HK1206971A1 - Methods for reducing cd36 expression cd36 - Google Patents
Methods for reducing cd36 expression cd36Info
- Publication number
- HK1206971A1 HK1206971A1 HK15107494.9A HK15107494A HK1206971A1 HK 1206971 A1 HK1206971 A1 HK 1206971A1 HK 15107494 A HK15107494 A HK 15107494A HK 1206971 A1 HK1206971 A1 HK 1206971A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- expression
- reducing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71817005P | 2005-09-16 | 2005-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206971A1 true HK1206971A1 (en) | 2016-01-22 |
Family
ID=37889419
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103915.7A HK1123992A1 (en) | 2005-09-16 | 2009-04-28 | Methods for reducing cd36 expression |
HK13100442.9A HK1173367A1 (en) | 2005-09-16 | 2009-04-28 | Methods for reducing cd36 expression cd36 |
HK15107494.9A HK1206971A1 (en) | 2005-09-16 | 2015-08-04 | Methods for reducing cd36 expression cd36 |
HK16100693.2A HK1212718A1 (zh) | 2005-09-16 | 2016-01-21 | 用於減少 表達的方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103915.7A HK1123992A1 (en) | 2005-09-16 | 2009-04-28 | Methods for reducing cd36 expression |
HK13100442.9A HK1173367A1 (en) | 2005-09-16 | 2009-04-28 | Methods for reducing cd36 expression cd36 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100693.2A HK1212718A1 (zh) | 2005-09-16 | 2016-01-21 | 用於減少 表達的方法 |
Country Status (10)
Country | Link |
---|---|
US (9) | US7541340B2 (xx) |
EP (5) | EP3095454A1 (xx) |
JP (6) | JP5416971B2 (xx) |
KR (9) | KR20140042940A (xx) |
CN (6) | CN102552874B (xx) |
AU (1) | AU2006292352B2 (xx) |
CA (8) | CA2947335A1 (xx) |
DK (1) | DK1931369T3 (xx) |
HK (4) | HK1123992A1 (xx) |
WO (1) | WO2007035640A2 (xx) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225574B (zh) | 2003-02-04 | 2017-01-11 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
EP2604621B1 (en) | 2003-05-01 | 2015-10-21 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
JP4931604B2 (ja) | 2004-01-23 | 2012-05-16 | コーネル リサーチ ファウンデイション インコーポレイテッド | 酸化的損傷を低減する方法 |
US7687243B1 (en) * | 2005-06-06 | 2010-03-30 | Crook Tonia M | Automated method for detecting apoptosis in cells |
CN102552874B (zh) * | 2005-09-16 | 2015-04-22 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
SI2252312T1 (sl) | 2008-02-07 | 2014-08-29 | Cornell University, | Postopki za preprečevanje ali zdravljenje insulinske rezistence |
JP5677096B2 (ja) * | 2008-02-26 | 2015-02-25 | コーネル ユニヴァーシティー | 急性腎障害を予防および治療するための方法 |
US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
EP3318264A1 (en) * | 2009-08-24 | 2018-05-09 | Stealth Peptides International, Inc. | Methods ans compositions for preventing or treating opthalmic conditions |
EP2764871A1 (en) * | 2009-10-05 | 2014-08-13 | Cornell University | Methods for the prevention or treatment of heart failure |
US20130190244A1 (en) * | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
CN103751763A (zh) * | 2009-12-31 | 2014-04-30 | 康肽德生物医药技术有限公司 | 用于预防或治疗血管阻塞损伤的方法 |
WO2011153209A2 (en) * | 2010-06-01 | 2011-12-08 | Cornell University | Cd36 inhibition to control obesity and insulin sensitivity |
EP2590664B1 (en) * | 2010-07-09 | 2019-03-27 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
EP2817018A4 (en) * | 2012-02-22 | 2015-09-23 | Stealth Peptides Int Inc | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS |
CN107320712A (zh) * | 2012-03-30 | 2017-11-07 | 康德生物医疗技术公司 | 用于预防和治疗神经病的方法和组合物 |
JP2015524439A (ja) * | 2012-08-02 | 2015-08-24 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
PL2936151T3 (pl) * | 2012-12-18 | 2018-11-30 | Biocrine Ab | Sposoby leczenia i/lub ograniczania rozwoju cukrzycy |
CA2912386A1 (en) * | 2013-05-14 | 2014-11-20 | Stealth Biotherapeutics Corp | Methods for the prevention or treatment of left ventricular remodeling |
WO2014210056A1 (en) * | 2013-06-27 | 2014-12-31 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
JP6434523B2 (ja) * | 2013-09-30 | 2018-12-05 | コーネル ユニヴァーシティー | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
WO2015089316A1 (en) * | 2013-12-12 | 2015-06-18 | Cornell University | Methods for preventing and treating oral cancers |
WO2015095077A1 (en) * | 2013-12-16 | 2015-06-25 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
JP7103787B2 (ja) | 2017-12-27 | 2022-07-20 | 太陽誘電株式会社 | コイル部品及び電子機器 |
US11392555B2 (en) | 2019-05-15 | 2022-07-19 | Pure Storage, Inc. | Cloud-based file services |
WO2021021452A1 (en) * | 2019-07-26 | 2021-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | 1,8-cineol coated implants |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
SG64368A1 (en) | 1988-06-30 | 1999-04-27 | Astra Ab | Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same |
US5602100A (en) | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
IS4261A (is) | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
EP0747092B1 (en) | 1995-06-09 | 2003-12-03 | Hisamitsu Pharmaceutical Co., Inc. | Matrix for iontophoresis |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
FR2756284B1 (fr) | 1996-11-26 | 2000-04-28 | Adir | Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6221355B1 (en) | 1997-12-10 | 2001-04-24 | Washington University | Anti-pathogen system and methods of use thereof |
CA2329709A1 (en) | 1998-04-24 | 1999-11-04 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
SE9900961D0 (sv) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
CA2386540A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
US6759520B1 (en) | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
US20050192215A1 (en) * | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
WO2003048326A2 (en) * | 2001-12-03 | 2003-06-12 | Nuvelo, Inc. | Methods and materials relating to novel polypeptides and polynucleotides |
AU2001277908A1 (en) * | 2000-07-18 | 2002-01-30 | Cornell Research Foundation Inc. | Medicinal uses of mu-opioid receptor agonists |
US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
CA2453140C (en) * | 2000-10-20 | 2016-01-05 | Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins and from the inhibition thereof |
DE10051983A1 (de) | 2000-10-20 | 2002-06-13 | Beate Kehrel | Inhibierung der pathogenen Wirkung oxidierter Proteine |
CA2447008A1 (en) | 2001-04-05 | 2002-10-24 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
US20070015146A1 (en) | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
JP4346870B2 (ja) * | 2002-07-05 | 2009-10-21 | キッコーマン株式会社 | 血糖値上昇抑制用組成物 |
US7785567B2 (en) * | 2002-08-23 | 2010-08-31 | Valorisation-Recherche, Société en Commandite | Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia |
CN104225574B (zh) | 2003-02-04 | 2017-01-11 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
US20040229901A1 (en) | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
EP2604621B1 (en) | 2003-05-01 | 2015-10-21 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
KR20060026011A (ko) | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
US20050012597A1 (en) | 2003-07-02 | 2005-01-20 | Anderson Peter Traneus | Wireless electromagnetic tracking system using a nonlinear passive transponder |
WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
EP1529533A1 (en) * | 2003-11-06 | 2005-05-11 | Sahltech I Göteborg AB | Use of GH secretagogues in hypoxic-ischemic brain injury |
KR20060114713A (ko) | 2003-12-12 | 2006-11-07 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | 멕신/RAGE/iNOS 발현 질환 모델동물 및 상기 동물을 사용한 화합물의 평가방법 |
JP4931604B2 (ja) * | 2004-01-23 | 2012-05-16 | コーネル リサーチ ファウンデイション インコーポレイテッド | 酸化的損傷を低減する方法 |
US20050272101A1 (en) | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US8157123B2 (en) * | 2005-02-23 | 2012-04-17 | The Glad Products Company | Container |
CN102552874B (zh) | 2005-09-16 | 2015-04-22 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
US20070259377A1 (en) * | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
US20080027082A1 (en) | 2006-06-19 | 2008-01-31 | Berthold Hocher | Use of adenosine a1 antagonists in radiocontrast media induced nephropathy |
SI2252312T1 (sl) * | 2008-02-07 | 2014-08-29 | Cornell University, | Postopki za preprečevanje ali zdravljenje insulinske rezistence |
JP5677096B2 (ja) | 2008-02-26 | 2015-02-25 | コーネル ユニヴァーシティー | 急性腎障害を予防および治療するための方法 |
JP2012181082A (ja) * | 2011-03-01 | 2012-09-20 | Tokyo Electric Power Co Inc:The | 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法 |
CN202756379U (zh) | 2012-07-13 | 2013-02-27 | 滨中元川金属制品(昆山)有限公司 | 一种自攻牙螺丝 |
-
2006
- 2006-09-18 CN CN201210028972.2A patent/CN102552874B/zh active Active
- 2006-09-18 CN CN2006800400192A patent/CN101296704B/zh active Active
- 2006-09-18 WO PCT/US2006/036291 patent/WO2007035640A2/en active Application Filing
- 2006-09-18 CN CN201310627156.8A patent/CN103784937B/zh active Active
- 2006-09-18 EP EP16176957.5A patent/EP3095454A1/en not_active Withdrawn
- 2006-09-18 DK DK06814864.2T patent/DK1931369T3/en active
- 2006-09-18 CA CA2947335A patent/CA2947335A1/en not_active Abandoned
- 2006-09-18 KR KR1020147007878A patent/KR20140042940A/ko not_active Application Discontinuation
- 2006-09-18 EP EP19160103.8A patent/EP3549594A1/en not_active Withdrawn
- 2006-09-18 AU AU2006292352A patent/AU2006292352B2/en active Active
- 2006-09-18 EP EP20167024.7A patent/EP3725324A1/en active Pending
- 2006-09-18 KR KR1020157000639A patent/KR20150013353A/ko not_active Application Discontinuation
- 2006-09-18 JP JP2008531412A patent/JP5416971B2/ja active Active
- 2006-09-18 CN CN201410509385.4A patent/CN104324360A/zh active Pending
- 2006-09-18 CA CA2947343A patent/CA2947343C/en active Active
- 2006-09-18 CA CA2947330A patent/CA2947330C/en active Active
- 2006-09-18 US US11/532,764 patent/US7541340B2/en active Active
- 2006-09-18 CA CA2947328A patent/CA2947328C/en active Active
- 2006-09-18 CN CN201610884213.4A patent/CN107412723A/zh active Pending
- 2006-09-18 CA CA2947340A patent/CA2947340C/en active Active
- 2006-09-18 KR KR1020147021832A patent/KR20140106761A/ko active Application Filing
- 2006-09-18 CA CA2947333A patent/CA2947333A1/en not_active Abandoned
- 2006-09-18 EP EP17172250.7A patent/EP3260127B1/en active Active
- 2006-09-18 KR KR1020087009150A patent/KR101426070B1/ko active IP Right Grant
- 2006-09-18 KR KR1020157000640A patent/KR101621493B1/ko active IP Right Grant
- 2006-09-18 CN CN201510142734.8A patent/CN104788540B/zh active Active
- 2006-09-18 CA CA2622911A patent/CA2622911C/en active Active
- 2006-09-18 CA CA2947341A patent/CA2947341C/en active Active
- 2006-09-18 EP EP06814864.2A patent/EP1931369B1/en active Active
-
2009
- 2009-04-28 HK HK09103915.7A patent/HK1123992A1/xx unknown
- 2009-04-28 HK HK13100442.9A patent/HK1173367A1/xx unknown
- 2009-05-01 US US12/434,216 patent/US7811987B2/en active Active
-
2010
- 2010-08-04 US US12/850,079 patent/US8603971B2/en active Active
-
2012
- 2012-08-17 JP JP2012181082A patent/JP5805596B2/ja active Active
-
2013
- 2013-01-17 JP JP2013006199A patent/JP5809649B2/ja active Active
- 2013-11-08 US US14/075,686 patent/US9150614B2/en active Active
-
2014
- 2014-05-22 US US14/285,226 patent/US20140256620A1/en not_active Abandoned
-
2015
- 2015-06-08 JP JP2015115856A patent/JP6157539B2/ja active Active
- 2015-08-04 HK HK15107494.9A patent/HK1206971A1/xx unknown
- 2015-08-07 JP JP2015156656A patent/JP6175107B2/ja active Active
-
2016
- 2016-01-21 HK HK16100693.2A patent/HK1212718A1/zh unknown
- 2016-05-09 KR KR1020160056491A patent/KR20160056863A/ko not_active Application Discontinuation
- 2016-05-10 KR KR1020160057030A patent/KR20160057372A/ko not_active Application Discontinuation
- 2016-12-05 US US15/369,281 patent/US20170305967A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000444A patent/JP6385476B2/ja active Active
- 2017-09-08 KR KR1020170115440A patent/KR101999756B1/ko active IP Right Grant
-
2018
- 2018-09-24 US US16/140,325 patent/US20190248833A1/en not_active Abandoned
-
2019
- 2019-07-08 KR KR1020190082102A patent/KR20190084025A/ko not_active Application Discontinuation
-
2020
- 2020-04-02 US US16/838,290 patent/US11447523B2/en active Active
-
2022
- 2022-08-03 US US17/880,271 patent/US20230212220A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212718A1 (zh) | 用於減少 表達的方法 | |
EP1864785A4 (en) | SETEROLITHOGRAPHIEVERFAHREN | |
GB0504774D0 (en) | Method | |
GB0503836D0 (en) | Method | |
GB0509433D0 (en) | Method | |
GB0504096D0 (en) | Method | |
GB0504184D0 (en) | Method | |
GB0507123D0 (en) | Method | |
GB0510536D0 (en) | Method | |
GB0525957D0 (en) | Methods | |
GB0508420D0 (en) | Method | |
GB0505756D0 (en) | Method | |
GB0502046D0 (en) | Method | |
GB0509305D0 (en) | Method | |
GB0509437D0 (en) | Method | |
GB0504182D0 (en) | Method | |
GB0715741D0 (en) | Methods | |
GB0518425D0 (en) | Methods | |
GB0516204D0 (en) | Methods | |
GB0526212D0 (en) | Methods | |
GB0509956D0 (en) | Method | |
GB0506670D0 (en) | Method | |
GB0502360D0 (en) | Method | |
GB0514661D0 (en) | Methods | |
GB0500607D0 (en) | Methods |